Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) open the trading on Wednesday, with great promise as it jumped 2.09% to $471.76, before settling in for the price of $462.11 at the close. Taking a more long-term approach, VRTX posted a 52-week range of $377.85-$519.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 28.35%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 4170.24%. This publicly-traded company’s shares outstanding now amounts to $256.94 million, simultaneously with a float of $255.90 million. The organization now has a market capitalization sitting at $121.14 billion. At the time of writing, stock’s 50-day Moving Average stood at $439.91, while the 200-day Moving Average is $463.29.
Vertex Pharmaceuticals, Inc (VRTX) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Vertex Pharmaceuticals, Inc’s current insider ownership accounts for 0.35%, in contrast to 93.14% institutional ownership. According to the most recent insider trade that took place on Feb 18 ’25, this organization’s EVP, Chief Reg. & Quality Off. sold 244 shares at the rate of 455.06, making the entire transaction reach 111,035 in total value, affecting insider ownership by 67,695. Preceding that transaction, on Feb 18 ’25, Company’s EVP and Chief Legal Officer sold 1,657 for 455.06, making the whole transaction’s value amount to 754,034. This particular insider is now the holder of 17,606 in total.
Vertex Pharmaceuticals, Inc (VRTX) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 4.34 per share during the current fiscal year.
Vertex Pharmaceuticals, Inc’s EPS increase for this current 12-month fiscal period is 4170.24% and is forecasted to reach 20.64 in the upcoming year.
Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) Trading Performance Indicators
Let’s observe the current performance indicators for Vertex Pharmaceuticals, Inc (VRTX). It’s Quick Ratio in the last reported quarter now stands at 2.35. The Stock has managed to achieve an average true range (ATR) of 12.55. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 11.03.
In the same vein, VRTX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.20, a figure that is expected to reach 4.26 in the next quarter, and analysts are predicting that it will be 20.64 at the market close of one year from today.
Technical Analysis of Vertex Pharmaceuticals, Inc (VRTX)
[Vertex Pharmaceuticals, Inc, VRTX] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 41.42% While, its Average True Range was 12.72.
Raw Stochastic average of Vertex Pharmaceuticals, Inc (VRTX) in the period of the previous 100 days is set at 66.12%, which indicates a major rise in contrast to 64.71% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 33.77% that was higher than 33.49% volatility it exhibited in the past 100-days period.
